|
MedChemExpress
recombinant mouse platelet derived growth factor bb Recombinant Mouse Platelet Derived Growth Factor Bb, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/platelet+derived+growth+factor/PDGF-BB%2C+Mouse/pm34512328-50-0-8 Average 90 stars, based on 1 article reviews
recombinant mouse platelet derived growth factor bb - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Abbexa Ltd
platelet derived growth factor c ![]() Platelet Derived Growth Factor C, supplied by Abbexa Ltd, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/platelet+derived+growth+factor/Platelet+Derived+Growth+Factor+D+Antibody/pmc10303399-118-27-31 Average 91 stars, based on 1 article reviews
platelet derived growth factor c - by Bioz Stars,
2026-11
91/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
platelet derived growth factor bb ![]() Platelet Derived Growth Factor Bb, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/platelet+derived+growth+factor/Human+PDGF-BB+(Platelet+Derived+Growth+Factor+BB)+ELISA+Kit/pm41906252-84-3-13 Average 94 stars, based on 1 article reviews
platelet derived growth factor bb - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
MedChemExpress
platelet derived growth factor ![]() Platelet Derived Growth Factor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/platelet+derived+growth+factor/PDGF-BB%2C+Human/pmc12927990-42-10-22 Average 94 stars, based on 1 article reviews
platelet derived growth factor - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
pdgf elisa kits ![]() Pdgf Elisa Kits, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/platelet+derived+growth+factor/Mouse+PDGF-AA+(Platelet+Derived+Growth+Factor+AA)+ELISA+Kit/bio_rxiv__340299-44-7-13 Average 93 stars, based on 1 article reviews
pdgf elisa kits - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
MedChemExpress
pdgfc ![]() Pdgfc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/platelet+derived+growth+factor/PDGF-CC%2C+Mouse/pm42886559-730-23-18 Average 94 stars, based on 1 article reviews
pdgfc - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
growth factor bb pdgf bb elisa kit ![]() Growth Factor Bb Pdgf Bb Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/platelet+derived+growth+factor/Rat+PDGF-BB+(Platelet+Derived+Growth+Factor+BB)+ELISA+Kit/pmc11164354-53-16-21 Average 94 stars, based on 1 article reviews
growth factor bb pdgf bb elisa kit - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
human platelet derived growth factor alpha polypeptide b pdgf ab elisa kit ![]() Human Platelet Derived Growth Factor Alpha Polypeptide B Pdgf Ab Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/platelet+derived+growth+factor/Human+PDGF-AB+(Platelet+Derived+Growth+Factor+AB)+ELISA+Kit/pm35282074-92-55-65 Average 92 stars, based on 1 article reviews
human platelet derived growth factor alpha polypeptide b pdgf ab elisa kit - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
MedChemExpress
pdgfrβ ![]() Pdgfrβ, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/platelet+derived+growth+factor/PDGFR+beta+Antibody/pmc09827684-14-1-5 Average 92 stars, based on 1 article reviews
pdgfrβ - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
TargetMol
cxcl1 ![]() Cxcl1, supplied by TargetMol, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/platelet+derived+growth+factor/CXCL1+Protein%2C+Mouse%2C+Recombinant/pm38654356-265-1-11 Average 92 stars, based on 1 article reviews
cxcl1 - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
pdgf bb ![]() Pdgf Bb, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/platelet+derived+growth+factor/Mouse+PDGF-BB+(Platelet+Derived+Growth+Factor+BB)+ELISA+Kit/pmc08370028-34-4-14 Average 94 stars, based on 1 article reviews
pdgf bb - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Cusabio
rat pdgf cc elisa kit ![]() Rat Pdgf Cc Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/platelet+derived+growth+factor/Rat+Platelet-derived+growth+factor+CC(PDGF-CC)+ELISA+kit/pm36587812-125-9-14 Average 91 stars, based on 1 article reviews
rat pdgf cc elisa kit - by Bioz Stars,
2026-11
91/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Pharmaceuticals
Article Title: Tocotrienol-Rich Fraction Ameliorates the Aluminium Chloride-Induced Neurovascular Dysfunction-Associated Vascular Dementia in Rats
doi: 10.3390/ph16060828
Figure Lengend Snippet: Microscopic images representing immunohistochemical staining of PDGF-C expression in the hippocampus (upper panel 40× magnification; scale bar 500 µm) and its corresponding CA1 area (lower panel 200× magnification; scale bar 100 µm). The high-magnification images in the lower panel indicate PDGF-C expression in the CA1 area. The PDGF-C expression is strongly positive in the CON group rats, faintly positive in the AlCl 3 and TRF 30 group rats, mid-positive in the TRF 60 and TRF 120 group rats, and strongly positive in the DON group rats. Abbreviations: AlCl 3 , aluminium chloride; CA1, cornu ammonis 1; CON, control; DON, donepezil; PDGF-C, platelet-derived growth factor-C; and TRF, tocotrienol-rich fraction.
Article Snippet: AlCl 3 (Friendemann Schmidt Chemical, Malaysia), myeloperoxidase activity assay kit (Elabscience Biotechnology Inc., Houston, TX, USA), nitrite assay kit (Sigma-Aldrich, St. Louis, MO, USA), rabbit polyclonal against
Techniques: Immunohistochemical staining, Staining, Expressing, Control, Derivative Assay
Journal: bioRxiv
Article Title: Corilagin controls post-parasiticide schistosome egg-induced liver fibrosis by inhibiting Stat6 signalling pathway
doi: 10.1101/340299
Figure Lengend Snippet: Effect of Corilagin on the expression of ARG1 according to ELISA. Data shown are the mean ± SD from 3 independent experiments. # P< 0.05 vs . normal group; *P< 0.05 VS model group; as determined by Student’s t-test; ## P< 0.01 determined by One-way ANOVA.
Article Snippet: The Mouse ARG1, Fizz1, Ym1, TGFβ and
Techniques: Expressing, Enzyme-linked Immunosorbent Assay
Journal: bioRxiv
Article Title: Corilagin controls post-parasiticide schistosome egg-induced liver fibrosis by inhibiting Stat6 signalling pathway
doi: 10.1101/340299
Figure Lengend Snippet: Effect of Corilagin on expression of PDGF, Fizz1, Ym1, and TGFβ according to ELISA. Data shown are the mean ± SD from 6 experiment mice. # P< 0.05, ## P< 0.01 vs . normal group; *P< 0.05, ** P< 0.01 VS model group; As determined by Student’s t-test; ### P< 0.01 determined by One-way ANOVA.
Article Snippet: The Mouse ARG1, Fizz1, Ym1, TGFβ and
Techniques: Expressing, Enzyme-linked Immunosorbent Assay
Journal: Journal of Translational Medicine
Article Title: Papillary thyroid cancer organoids harboring BRAF V600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
doi: 10.1186/s12967-022-03848-z
Figure Lengend Snippet: List of drugs used in this study
Article Snippet: VEGFR,
Techniques: DNA Synthesis
Journal: Journal of experimental & clinical cancer research : CR
Article Title: Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.
doi: 10.1186/s13046-024-03050-7
Figure Lengend Snippet: Fig. 3 EV-dead promotes the invasion and BCSC subpopulation of the co-cultured human TNBC MDA-MB-231 cells by inducing macrophage M2 polarization. A Diagram of the EV-deadADR and EV-alive-H separation procedures and their representative TEM images. Scale bar: 100 nm. B EV protein markers were identified by Western blotting; (C) EV sizes and concentrations were detected by NTA analysis; (D) CXCL1 concentrations in EV-deadADR and EV-alive-H were detected by an ELISA assay; (E, F) The polarization changes of THP1 macrophages after EV-deadADR treatment (25–100 μg/ml) for 48 h; 50 μg/ml EV-dead was used for the Western blotting assay; G Invasion efficacy changes of the co-cultured MDA-MB-231 cells after EV-deadADR treatment as indicated. Scale bars: 100 μm; H Changes in apoptosis resistance of the co-cultured MDA-MB-231 cells to paclitaxel after EV-deadADR treatment for 48 h, as determined by annexin V-FITC/PI staining and flow cytometry; I The ALDH+ BCSC subpopulation and CD133+ BCSC subpopulation in the co-cultured MDA-MB-231 cells after EV-deadADR treatment for 48 h were detected by flow cytometry; n = 3. Data are presented as mean ± SD. *p < 0.05, **p < 0.01
Article Snippet: As
Techniques: Cell Culture, Western Blot, Enzyme-linked Immunosorbent Assay, Staining, Flow Cytometry
Journal: Journal of experimental & clinical cancer research : CR
Article Title: Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.
doi: 10.1186/s13046-024-03050-7
Figure Lengend Snippet: Fig. 4 CXCL1EV-dead induces macrophage M2 polarization by activating PD-L1 expression. A Chemokine array assay was conducted to characterize the differences in chemokine content between EV-dead and EV-alive. An ELISA assay was conducted to compare the relative CXCL1 content in EV-dead and EV-alive. B Changes in M2 phenotype polarization of Raw264.7 macrophages when treated with 10 ng/ml murine CXCL1, 50 μg/ ml EV-dead, 50 μg/ml EV-deadshCXCL1, 5 μg/ml CXCL1 neutralizing antibody (NA), or EV-dead and CXCL1-NA combination for 48 h. C Representative images of Transwell assay. Raw264.7 macrophages were treated as indicated for 48 h and then co-cultured with 4 T1 cells. Scale bar: 200 μm. D–F Expression changes of CXCL1 and PD-L1 in Raw264.7 macrophages when treated as indicated for 48 h. Scale bar: 10 μm. G The results of the flow cytometry assay suggested that 50 μg/ml EV-dead treatment for 48 h induced the M2 polarization of Raw264.7 macrophages by activating PD-L1 expression; n = 3. Data are presented as mean ± SD. *p < 0.05, **p < 0.01
Article Snippet: As
Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Transwell Assay, Cell Culture, Flow Cytometry
Journal: Journal of experimental & clinical cancer research : CR
Article Title: Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.
doi: 10.1186/s13046-024-03050-7
Figure Lengend Snippet: Fig. 5 CXCL1EV-dead promotes TNBC growth and lung metastasis in vivo by activating TAM/PD-L1 signaling. A The successful generation of 4 T1/rCXCL1Flag cells was validated by immunoblotting and immunofluorescence assays. Scale bar: 5 μm. B The difference in CXCL1 content between EV-dead and EV-deadrCXCL1-Flag was compared by ELISA. EV-deadrCXCL1-Flag was isolated from the supernatants of apoptotic 4 T1/rCXCL1Flag cells induced by paclitaxel treatment; n = 3. C, D Peritumoral injection with EV-deadrCXCL1 (200 μg/20 g weight, q3d) significantly accelerated TNBC growth (C) and lung metastasis (D) compared to that of the EV-dead group (200 μg/20 g weight, q3d); Tumor volume: n = 6; Number of metastatic lesions, n = 3; K-M curves of lung metastasis time, n = 10. Scale bar: 1 cm. E Tumor tissue immunofluorescence experiment showed that flag-tagged CXCL1 (red) from EV-deadrCXCL1-Flag was predominantly phagocytosed by CD206+ macrophages (green) in the TME. Scale bar: 5 μm. F The infiltration levels of CD45+/F4/80+/CD206+ TAMs (up) and CD45+/F4/80+/PD-L1+ TAMs (down) in the TME of mice following treatment with saline, EV-dead, or EV-deadrCXCL1-Flag; n = 3. G QPCR assay was conducted to investigate the CTC quantity in the peripheral blood of mice following treatment with saline, EV-dead, or EV-deadrCXCL1-Flag; n = 3. Data are presented as mean ± SD. *p < 0.05, **p < 0.01
Article Snippet: As
Techniques: In Vivo, Western Blot, Immunofluorescence, Enzyme-linked Immunosorbent Assay, Isolation, Injection, Saline
Journal: Journal of experimental & clinical cancer research : CR
Article Title: Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.
doi: 10.1186/s13046-024-03050-7
Figure Lengend Snippet: Fig. 6 CXCL1 knockdown in EV-dead or macrophage depletion inhibits EV-dead-induced TNBC growth and lung metastasis in vivo. A The successful generation of 4 T1/shCXCL1 cells was verified by western blotting assay. The difference in CXCL1 content between EV-dead and EV-deadshCXCL1 was compared by ELISA. EV-deadshCXCL1 was isolated from the supernatants of apoptotic 4 T1/shCXCL1 cells induced by paclitaxel treatment; n = 3. B Representative images of the tumors (n = 7) and the in vivo imaging assay (n = 3), and mouse weight and tumor volume curves (n = 7). Clodronate liposomes (CL) were used to deplete macrophages in the TME of the 4 T1-Luc xenograft model. Scale bar: 2 cm. C Representative images of the lungs (n = 3) and lung HE assay (n = 3) as well as the K-M curves of lung metastasis time (n = 10). Scale bar: 100 μm. D, E The infiltration levels of CD45+/F4/80+/CD206+ TAMs (D) and CD45+/F4/80+/PD-L1+ TAMs (E) in the TME of mice following treatment with EV-dead, EV-deadshCXCL1, or the combination of EV-dead and CL; n = 3. F CD206 (green) and PD-L1 (red) expression levels in the TME. Arrows indicate PD-L1 expression in TAMs. Scale bar: 10 μm. G The quantity of CTCs in the peripheral blood of mice treated as indicated; n = 3. Data are presented as mean ± SD. *p < 0.05, **p < 0.01
Article Snippet: As
Techniques: Knockdown, In Vivo, Western Blot, Enzyme-linked Immunosorbent Assay, Isolation, In Vivo Imaging, Liposomes, Expressing
Journal: Journal of experimental & clinical cancer research : CR
Article Title: Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.
doi: 10.1186/s13046-024-03050-7
Figure Lengend Snippet: Fig. 7 CXCL1EV-dead transcriptionally increases PD-L1 expression in macrophages by activating EED signaling. A The mRNA level of PD-L1 in Raw264.7 macrophages was significantly increased by 10 ng/ml murine CXCL1 and 50 μg/ml EV-dead treatment for 24 h; (B) The promoter activity of PD-L1 in Raw264.7 cells when treated as indicated for 24 h; CXCL1-NA concentration: 5 μg/ml; (C) Diagram of the DNA-pull down-MS assay. The DEPs that bind with the PD-L1 promoter region of Raw264.7 macrophages after CXCL1 treatment for 24 h were analyzed by mass spectrometry. The TFs of PD-L1 were predicted using the hTFtarget database. EED was selected as the potential transcription factor by taking the intersection of the DEP set and the TF set. D, E The expression levels of EED and PD-L1 in Raw264.7 cells when treated as indicated for 48 h. Murine CXCL1 concentration: 10 ng/ml. Scale bar: 5 μm. F The combinational effect of CXCL1 treatment and EED knockdown on the promoter activity of PD-L1 in Raw264.7 cells when treated as indicated for 24 h; (G) The binding activity of EED with the promoter fragment of PD-L1 in Raw264.7 cells when treated as indicated for 48 h was investigated by CHIP-PCR assay. H The antisense mutation of the EED binding region in the PD-L1 promoter significantly abrogated the induction effect of CXCL1 on PD-L1 promoter activity in Raw264.7 macrophages; n = 3. Data are presented as mean ± SD. *p < 0.05, **p < 0.01
Article Snippet: As
Techniques: Expressing, Activity Assay, Concentration Assay, Mass Spectrometry, Knockdown, Binding Assay, Mutagenesis
Journal: Journal of experimental & clinical cancer research : CR
Article Title: Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.
doi: 10.1186/s13046-024-03050-7
Figure Lengend Snippet: Fig. 8 TPCA-1 significantly inhibits CXCL1EV-dead-EV-dead-induced chemoresistance and invasion of TNBC cells co-cultured with macrophages. A, B Diagram of the CXCL1 secretion inhibitor screening assay. 4 T1 cells were treated with 80 kinds of compounds (1 μM) for 48 h, and the top five compounds with the strongest inhibitory activities on CXCL1 secretion of 4 T1 cells were selected; n = 3. C, D The cytotoxicity of TPCA-1 in TNBC 4 T1 cells (n = 8) and its effect on the apoptosis resistance of 4 T1 cells to paclitaxel (n = 3). Cells were treated as indicated for 48 h. E–G TPCA-1 treatment for 48 h had no significant effect on EV-dead secretion (E) from 4 T1 cells but significantly attenuated the concentration of CXCL1 in the supernatants of 4 T1 cells (F) and the EV-dead of apoptotic 4 T1 cells (G); n = 3. H The results of the flow cytometry assay indicated that 1 μM TPCA-1 treatment for 48 h significantly reversed the induction effect of EV-dead (50 μg/ml) on the M2 polarization of macrophages; n = 3. I, J Apoptosis and Transwell assays suggested that TPCA-1 treatment (1 μM) for 48 h inhibited 50 μg/ml EV-dead-induced apoptosis resistance (n = 3) and invasion (n = 3) of 4 T1 cells in the co-culture system; Scale bar: 100 μm. Data are presented as mean ± SD. *p < 0.05, **p < 0.01
Article Snippet: As
Techniques: Cell Culture, Screening Assay, Concentration Assay, Flow Cytometry, Co-Culture Assay
Journal: Pharmacological research
Article Title: Remote ischemic conditioning attenuates blood-brain barrier disruption after recombinant tissue plasminogen activator treatment via reducing PDGF-CC.
doi: 10.1016/j.phrs.2022.106641
Figure Lengend Snippet: Fig. 4. RIPreC attenuated the phosphorylation of PDGFRα in ischemic brain tissue by reducing the blood levels of PDGF-CC. (A-C) Western blot and quantification of phosphorylated and total PDGFRα in ischemic penumbra cortex at 24 h after intravenous thrombolysis (n = 6 rats per group). Three representative samples were shown. * ** P < 0.001, two-way ANOVA. Data represent mean ± SEM. (D) ELISA analysis of serum PDGF-CC at 24 h after intravenous thrombolysis. (n = 6–9 rats per group). Sham rats received only anesthesia without RIC procedure, while RIPreC rats received both procedures before stroke. * ** P < 0.001, two-way ANOVA. Data represent mean ± SEM. (E) The schematic protocol for healthy rats receiving RIC treatment. Serum samples were collected at day 0 (baseline), day 1, day 7 of RIC, and 24 h after the last RIC procedure (day 8). (F) ELISA analysis of serum PDGF-CC in non-stroke rats after RIC or sham-operation (n = 8 rats per group). Sham rats received only anesthesia without RIC procedure, while RIPreC rats received both procedures. ** P < 0.01, * ** P < 0.001, two-way ANOVA. Data represent mean ± SEM. (G) The schematic protocol for healthy humans receiving 7-day RIC treatment. (H-I) ELISA analysis of serum PDGF-CC levels in 30 healthy humans. One-way ANOVA. Data represent mean ± SEM.
Article Snippet: The rat PDGF-CC protein level was measured using a
Techniques: Phospho-proteomics, Western Blot, Enzyme-linked Immunosorbent Assay
Journal: Pharmacological research
Article Title: Remote ischemic conditioning attenuates blood-brain barrier disruption after recombinant tissue plasminogen activator treatment via reducing PDGF-CC.
doi: 10.1016/j.phrs.2022.106641
Figure Lengend Snippet: Fig. 6. RIC reduces circulating PDGF-CC levels by reducing the PDGF-CC level in the skeletal muscle from RIC-treated hindlimbs and blood platelets. (A-C) Western blot and qRT-PCR analysis of Hif-1α levels in the hindlimbs skeletal muscles receiving RIC or sham procedure. Healthy rats received RIC or sham operation for 7 days and the skeletal muscles from the treated hindlimbs were harvested 24 h after the last round of RIC. Three representative samples were shown (n = 6 rats per group). * P < 0.05, unpaired t-test. Data represent mean ± SEM. (D-F) Western blot analysis of PDGF-CC levels in the skeletal muscles of the hindlimbs receiving RIC or sham procedure (n = 8 rats per group). Three representative samples were shown. Unpaired t-test, * ** P < 0.001. Data represent mean ± SEM. (G-H) ELISA and qRT-PCR analysis of PDGF-CC protein and Pdgfc mRNA levels in the hindlimbs skeletal muscles receiving RIC or sham procedure (n = 8 rats per group) * P < 0.05, * * P < 0.01, unpaired t-test. Data represent mean ± SEM. (I-J) Platelets analysis from blood routine examination in rats received RIC or sham procedure. The blood samples were obtained via inferior vena cava of rats which received a 7-day RIC or sham operation (n = 9 rats per group). Unpaired t-test, * P < 0.05. Data represent mean ± SEM. (K-L) ELISA analysis of PDGF-CC level from platelets or plasma in healthy rats after RIC or sham operation (n = 10 rats per group). Unpaired t-test, * P < 0⋅05. Data represent mean ± SEM. (M) ELISA analysis of PDGF-CC level from indicated tissues harvested from healthy rats after RIC or sham operation (n = 6 rats per group). * ** P < 0.001, Unpaired t-test. Data represent mean ± SEM.
Article Snippet: The rat PDGF-CC protein level was measured using a
Techniques: Western Blot, Quantitative RT-PCR, Muscles, Enzyme-linked Immunosorbent Assay, Clinical Proteomics
Journal: Pharmacological research
Article Title: Remote ischemic conditioning attenuates blood-brain barrier disruption after recombinant tissue plasminogen activator treatment via reducing PDGF-CC.
doi: 10.1016/j.phrs.2022.106641
Figure Lengend Snippet: Fig. 7. The protective effect of RIPostC on BBB integrity was also dependent on reduction of the blood PDGF-CC levels. (A) The schematic protocol for RIPostC intervention in rats with embolic stroke. (B-C) Representative images of TTC staining at 72 h after intravenous thrombolysis (n = 8 rats per group). Sham rats received only anesthesia without RIC procedure, while RIPostC rats received both procedures after thrombolysis. * P < 0.05, unpaired t-test. Data represent mean ± SEM. (D) Neurological deficit score at 1 and 3 days after intravenous thrombolysis (n = 10 rats per group). * P < 0.05, two-way ANOVA. Data represent mean ± SEM. (E) qRT-PCR analysis of IL-1β, IL-6, and TNF-α mRNA levels. (n = 8 rats per group). * * P < 0.01, * ** P < 0.001, unpaired t-test. Data represent mean ± SEM. (F) ELISA analysis of serum PDGF-CC (n = 10 rats per group). * * P < 0.01, two-way ANOVA. Data represent mean ± SEM. (G-H) Evans blue leakage at 72 h post intravenous thrombolysis. Recombinant PDGF-CC or normal saline were intravenously injected before and at 24 h and 48 h after thrombolysis (n = 9 rats per group). * P < 0.05, * * P < 0.01, one-way ANOVA. Data represent mean ± SEM. (I-J) The schematic protocol and ELISA analysis for RIPostC intervention in AIS patients with intravenous thrombolysis. Participants received two administrations of RIPostC (22 patients) or sham (20 patients) treatment at 6 h for the first round and 18 h for the second round after intravenous thrombolysis. Unpaired t-test. Data represent mean ± SEM.
Article Snippet: The rat PDGF-CC protein level was measured using a
Techniques: Staining, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Recombinant, Saline, Injection